Altoida's medical diagnostic application uses machine-learning algorithms and longitudinal clinical studies to detect Alzheimer's and dementia before onset. Their products are backed by over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's first device, a Computerized Cognitive Assessment Aid, is FDA Breakthrough Device Designated and classified as Class II, 510(k) exempt.